Fundacao Faculdade de Medicina Instituto do Cancer do Estado de Sao Paulo

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Bladder cancer5 trials
• Prostate cancer4 trials
• Lung cancer3 trials
• Childhood cancers2 trials
• Colorectal cancer2 trials
• Head and neck cancer1 trial

Phase

• Phase 313 trials
• Phase 23 trials
• Phase 1/21 trial

Status

• Active, not recruiting10 trials
• Recruiting5 trials
• Completed2 trials

Lead sponsor

• Janssen Research & Development, LLC16 trials
• Johnson & Johnson Enterprise Innovation Inc.1 trial

Running trials

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

  NCT06120140· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

  NCT05884398· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Johnson & Johnson Enterprise Innovation Inc.· Source

• Recruiting

  A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

  NCT04811560· Phase 1/2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

  NCT04658862· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

  NCT04538664· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04487080· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

  NCT04497844· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

  NCT03767244· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

  NCT03748641· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Head and neck cancer1 recruiting

Closed trials

• Completed

  A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  NCT04172675· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Janssen Research & Development, LLC· Source